{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:44:52Z","timestamp":1790347492457,"version":"4.1.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Science and technology project of the health planning committee of Sichuan","award":["21PJ050"],"award-info":[{"award-number":["21PJ050"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The emergence of malignant ascites (MA) indicates poor prognoses in patients with ovarian, gastrointestinal, breast, and pancreatic cancer. Interleukin-10 (IL-10) is a pleiotropic cytokine with immunoregulatory effects in tumor microenvironment. The level of IL-10 in MA varied across cancer types and patients, influencing cancer progression and outcomes. Originating from various immune and cancer cells, IL-10 contributes to complex signaling pathways in MA. Systemic IL-10 administration, although the evidence of its efficacy on MA is limited, still emerges as a promising therapeutic strategy because it can increase CD8+ T cells cytotoxicity and invigorate exhausted CD8+ tumor infiltration lymphocytes (TILs) directly. IL-10 signaling blockade also demonstrates great potential when combined with other immunotherapies in MA treatment. We reviewed the levels, origins, and functions of IL-10 in malignant ascites and overviewed the current IL-10 signaling targeting therapies, aiming to provide insights for MA treatment.<\/jats:p>","DOI":"10.1007\/s00262-023-03616-y","type":"journal-article","created":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T06:02:21Z","timestamp":1706335341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The complex role of IL-10 in malignant ascites: a review"],"prefix":"10.1007","volume":"73","author":[{"given":"Yue","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangni","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,27]]},"reference":[{"issue":"5","key":"3616_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ejca.2005.11.018","volume":"42","author":"GGD Becker","year":"2006","unstructured":"Becker GGD, Blum HE (2006) Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 42(5):589\u2013597","journal-title":"Eur J Cancer"},{"issue":"8","key":"3616_CR2","first-page":"3353","volume":"29","author":"HSJ Woopen","year":"2009","unstructured":"Woopen HSJ (2009) Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res 29(8):3353\u20133359","journal-title":"Anticancer Res"},{"issue":"1","key":"3616_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.tice.2016.11.004","volume":"49","author":"JO van Baal","year":"2017","unstructured":"van Baal JO, Van de Vijver KK, Nieuwland R, van Noorden CJ, van Driel WJ, Sturk A et al (2017) The histophysiology and pathophysiology of the peritoneum. Tissue Cell 49(1):95\u2013105","journal-title":"Tissue Cell"},{"issue":"3\u20134","key":"3616_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF00665960","volume":"12","author":"DR Senger","year":"1993","unstructured":"Senger DR, de Van Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK et al (1993) Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12(3\u20134):303\u2013324","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"3616_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-012-0396-6","volume":"18","author":"E Cavazzoni","year":"2013","unstructured":"Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A (2013) Malignant ascites: pathophysiology and treatment. Int J Clin Oncol 18(1):1\u20139","journal-title":"Int J Clin Oncol"},{"issue":"17","key":"3616_CR6","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.3390\/cancers13174318","volume":"13","author":"BP Rickard","year":"2021","unstructured":"Rickard BP, Conrad C, Sorrin AJ, Ruhi MK, Reader JC, Huang SA et al (2021) Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response. Cancers (Basel) 13(17):4318","journal-title":"Cancers (Basel)"},{"issue":"4","key":"3616_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3109\/00365513.2013.773593","volume":"73","author":"B Liang","year":"2013","unstructured":"Liang B, Guo Z, Li Y, Liu C (2013) Elevated VEGF concentrations in ascites and serum predict adverse prognosis in ovarian cancer. Scand J Clin Lab Invest 73(4):309\u2013314","journal-title":"Scand J Clin Lab Invest"},{"issue":"10","key":"3616_CR8","doi-asserted-by":"publisher","first-page":"9653","DOI":"10.1074\/jbc.M306662200","volume":"279","author":"X Fang","year":"2004","unstructured":"Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX et al (2004) Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 279(10):9653\u20139661","journal-title":"J Biol Chem"},{"issue":"8","key":"3616_CR9","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1002\/1097-0142(19931015)72:8<2433::AID-CNCR2820720822>3.0.CO;2-L","volume":"72","author":"MM Moradi","year":"1993","unstructured":"Moradi MM, Carson LF, Weinberg B, Haney AF, Twiggs LB, Ramakrishnan S (1993) Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer 72(8):2433\u20132440","journal-title":"Cancer"},{"issue":"1","key":"3616_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13048-017-0320-9","volume":"10","author":"O Sipak-Szmigiel","year":"2017","unstructured":"Sipak-Szmigiel O, Wlodarski P, Ronin-Walknowska E, Niedzielski A, Karakiewicz B, Sluczanowska-Glabowska S et al (2017) Serum and peritoneal fluid concentrations of soluble human leukocyte antigen, tumor necrosis factor alpha and interleukin 10 in patients with selected ovarian pathologies. J Ovarian Res 10(1):25","journal-title":"J Ovarian Res"},{"issue":"6","key":"3616_CR11","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jamcollsurg.2004.01.035","volume":"198","author":"RA Adam","year":"2004","unstructured":"Adam RA, Adam YG (2004) Malignant ascites: past, present, and future. J Am Coll Surg 198(6):999\u20131011","journal-title":"J Am Coll Surg"},{"issue":"2","key":"3616_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF00210790","volume":"14","author":"S Wojtowicz-Praga","year":"1996","unstructured":"Wojtowicz-Praga S, Low J, Marshall J, Ness E, Dickson R, Barter J et al (1996) Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drugs 14(2):193\u2013202","journal-title":"Invest New Drugs"},{"issue":"6","key":"3616_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S0748-7983(97)93077-8","volume":"23","author":"SL Parsons","year":"1997","unstructured":"Parsons SL, Watson SA, Steele RJ (1997) Phase I\/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol 23(6):526\u2013531","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"3616_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/clon.2002.0135","volume":"15","author":"EM Smith","year":"2003","unstructured":"Smith EM, Jayson GC (2003) The current and future management of malignant ascites. Clin Oncol (R Coll Radiol) 15(2):59\u201372","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"3616_CR15","first-page":"414019","volume":"2015","author":"A Miyoshi","year":"2015","unstructured":"Miyoshi A, Miyatake T, Hara T, Tanaka A, Komura N, Komiya S et al (2015) Etiology of ascites and pleural effusion associated with ovarian tumors: literature review and case reports of three ovarian tumors presenting with massive ascites, but without peritoneal dissemination. Case Rep Obstet Gynecol 2015:414019","journal-title":"Case Rep Obstet Gynecol"},{"issue":"1","key":"3616_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/jso.25453","volume":"120","author":"C Hodge","year":"2019","unstructured":"Hodge C, Badgwell BD (2019) Palliation of malignant ascites. J Surg Oncol 120(1):67\u201373","journal-title":"J Surg Oncol"},{"issue":"19","key":"3616_CR17","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.3390\/cancers13194873","volume":"13","author":"HIM Chen","year":"2021","unstructured":"Chen HIM, Horita N, Tanzawa S, Kazahari H, Ochiai R, Sakamoto T, Honda T, Ichikawa Y, Watanabe K, Seki N (2021) Effectiveness of cell-free and concentrated ascites reinfusion therapy in the treatment of malignancy-related ascites: a systematic review and meta-analysis. Cancers (Basel) 13(19):4873","journal-title":"Cancers (Basel)"},{"key":"3616_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/CMAR.S100210","volume":"9","author":"M Stukan","year":"2017","unstructured":"Stukan M (2017) Drainage of malignant ascites: patient selection and perspectives. Cancer Manag Res 9:115\u2013130","journal-title":"Cancer Manag Res"},{"key":"3616_CR19","first-page":"309","volume":"2","author":"D Seimetz","year":"2011","unstructured":"Seimetz D (2011) Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab). J Cancer Res Clin Oncol 2:309\u2013316","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"3616_CR20","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1002\/ijc.25423","volume":"127","author":"MM Heiss","year":"2010","unstructured":"Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV et al (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial. Int J Cancer 127(9):2209\u20132221","journal-title":"Int J Cancer"},{"issue":"8","key":"3616_CR21","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1093\/annonc\/mds178","volume":"23","author":"P Wimberger","year":"2012","unstructured":"Wimberger P, Gilet H, Gonschior AK, Heiss MM, Moehler M, Oskay-Oezcelik G et al (2012) Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II\/III study comparing paracentesis plus catumaxomab with paracentesis alone. Ann Oncol 23(8):1979\u20131985","journal-title":"Ann Oncol"},{"issue":"5","key":"3616_CR22","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s10637-016-0369-0","volume":"34","author":"N Takahara","year":"2016","unstructured":"Takahara N, Isayama H, Nakai Y, Ishigami H, Satoi S, Mizuno S et al (2016) Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. Invest New Drugs 34(5):636\u2013642","journal-title":"Invest New Drugs"},{"key":"3616_CR23","unstructured":"NCCN (2022) The NCCN ovarian cancer clinical practice guidelines in oncology (version 5.2022). https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1453"},{"issue":"1","key":"3616_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ygyno.2015.07.103","volume":"139","author":"JS Ferriss","year":"2015","unstructured":"Ferriss JS, Java JJ, Bookman MA, Fleming GF, Monk BJ, Walker JL et al (2015) Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology\/GOG study. Gynecol Oncol 139(1):17\u201322","journal-title":"Gynecol Oncol"},{"key":"3616_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejca.2016.05.004","volume":"63","author":"KLT Jordan","year":"2016","unstructured":"Jordan KLT, Gog C, Killing B, Arnold D, Hinke A, Stahl M, Freier W, R\u00fcssel J, Atanackovic D, Hegewisch-Becker S (2016) Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: a multicentre double-blind, placebo-controlled phase II study\u2014AIO SUP-0108. Eur J Cancer 63:127\u2013134","journal-title":"Eur J Cancer"},{"issue":"8","key":"3616_CR26","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1007\/s00464-013-2800-3","volume":"27","author":"MC Ba","year":"2013","unstructured":"Ba MC, Long H, Cui SZ, Tang YQ, Wu YB, Zhang XL et al (2013) Multivariate comparison of B-ultrasound guided and laparoscopic continuous circulatory hyperthermic intraperitoneal perfusion chemotherapy for malignant ascites. Surg Endosc 27(8):2735\u20132743","journal-title":"Surg Endosc"},{"key":"3616_CR27","unstructured":"NCCN (2022) The NCCN gastric cancer clinical practice guidelines in oncology (version 2.2022). https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1434"},{"key":"3616_CR28","unstructured":"NCCN (2022) The NCCN colon cancer clinical practice guidelines in oncology (version 2.2022). https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1428"},{"issue":"3","key":"3616_CR29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00262-014-1636-6","volume":"64","author":"JH\u00d8 Landskron","year":"2015","unstructured":"Landskron JH\u00d8, Torgersen KM, Aandahl EM, Gjertsen BT, Bj\u00f8rge L, Task\u00e9n K (2015) Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunol Immunother 64(3):337\u2013347","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"3616_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.canlet.2015.07.009","volume":"367","author":"MHZZ Mannino","year":"2015","unstructured":"Mannino MHZZ, Xiao H, Bai Q, Wakefield MR, Fang Y (2015) The paradoxical role of IL-10 in immunity and cancer. Cancer Lett 367(2):103\u2013107","journal-title":"Cancer Lett"},{"issue":"2","key":"3616_CR31","first-page":"122","volume":"21","author":"A Rabinovich","year":"2010","unstructured":"Rabinovich A, Medina L, Piura B, Huleihel M (2010) Expression of IL-10 in human normal and cancerous ovarian tissues and cells. Eur Cytokine Netw 21(2):122\u2013128","journal-title":"Eur Cytokine Netw"},{"issue":"3","key":"3616_CR32","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/147323000703500302","volume":"35","author":"JYF Zhou","year":"2007","unstructured":"Zhou JYF, Chen H, Lv W, Gan N (2007) The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines. J Int Med Res 35(3):290\u2013300","journal-title":"J Int Med Res"},{"issue":"5","key":"3616_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/1043-4666(92)90082-3","volume":"4","author":"WHAJ Gotlieb","year":"1992","unstructured":"Gotlieb WHAJ, Watson JM, Velu TJ, Berek JS, Mart\u00ednez-Maza O (1992) Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokine 4(5):385\u2013390","journal-title":"Cytokine"},{"issue":"1","key":"3616_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cyto.2008.10.019","volume":"45","author":"A Mustea","year":"2009","unstructured":"Mustea A, Braicu EI, Koensgen D, Yuan S, Sun PM, Stamatian F et al (2009) Monitoring of IL-10 in the serum of patients with advanced ovarian cancer: results from a prospective pilot-study. Cytokine 45(1):8\u201311","journal-title":"Cytokine"},{"issue":"3","key":"3616_CR35","first-page":"375","volume":"31","author":"MGE Nowak","year":"2010","unstructured":"Nowak MGE, Szpakowski M, Szyllo K, Malinowski A, Kulig A, Tchorzewski H, Wilczynski J (2010) Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett 31(3):375\u2013383","journal-title":"Neuro Endocrinol Lett"},{"issue":"4","key":"3616_CR36","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1183\/09031936.00129306","volume":"30","author":"EML Zeni","year":"2007","unstructured":"Zeni EML, Miotto D, Lo Cascio N, Maestrelli P, Querzoli P, Pedriali M, De Rosa E, Fabbri LM, Mapp CE, Boschetto P (2007) Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J 30(4):627\u2013632","journal-title":"Eur Respir J"},{"issue":"1","key":"3616_CR37","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13059-016-0956-6","volume":"17","author":"S Reinartz","year":"2016","unstructured":"Reinartz S, Finkernagel F, Adhikary T, Rohnalter V, Schumann T, Schober Y et al (2016) A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome. Genome Biol 17(1):108","journal-title":"Genome Biol"},{"issue":"5","key":"3616_CR38","first-page":"566","volume":"2","author":"ILD Matte","year":"2012","unstructured":"Matte ILD, Laplante C, Rancourt C, Pich\u00e9 A (2012) Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res 2(5):566\u2013580","journal-title":"Am J Cancer Res"},{"issue":"1","key":"3616_CR39","first-page":"60","volume":"17","author":"EBJ Lech-Maranda","year":"2006","unstructured":"Lech-Maranda EBJ, Michallet AS, Houot R, Robak T, Coiffier B, Salles G (2006) Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. Eur Cytokine Netw 17(1):60\u201366","journal-title":"Eur Cytokine Netw"},{"issue":"10","key":"3616_CR40","doi-asserted-by":"publisher","first-page":"bqaa062","DOI":"10.1210\/endocr\/bqaa062","volume":"161","author":"ZW Lu","year":"2020","unstructured":"Lu ZW, Hu JQ, Liu WL, Wen D, Wei WJ, Wang YL et al (2020) IL-10 restores MHC class I expression and interferes with immunity in papillary thyroid cancer with hashimoto thyroiditis. Endocrinology 161(10):bqaa062","journal-title":"Endocrinology"},{"issue":"2","key":"3616_CR41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00262-016-1924-4","volume":"66","author":"LL Cunha","year":"2017","unstructured":"Cunha LL, Morari EC, Nonogaki S, Marcello MA, Soares FA, Vassallo J et al (2017) Interleukin 10 expression is related to aggressiveness and poor prognosis of patients with thyroid cancer. Cancer immunol immunother CII 66(2):141\u2013148","journal-title":"Cancer immunol immunother CII"},{"issue":"7","key":"3616_CR42","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1023\/A:1008375208574","volume":"11","author":"HAY Hatanaka","year":"2000","unstructured":"Hatanaka HAY, Kamiya T, Morino F, Nagata J, Tokunaga T, Oshika Y, Suemizu H, Kijima H, Tsuchida T, Yamazaki H, Inoue H, Nakamura M, Ueyama Y (2000) Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann Oncol 11(7):815\u2013819","journal-title":"Ann Oncol"},{"issue":"5","key":"3616_CR43","first-page":"1785","volume":"9","author":"JCMC Soria","year":"2003","unstructured":"Soria JCMC, Kemp BL, Liu DD, Feng L, Tang X, Chang YS, Mao L, Khuri FR (2003) Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 9(5):1785\u20131791","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3616_CR44","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00262-017-2106-8","volume":"67","author":"N Ahmad","year":"2018","unstructured":"Ahmad N, Ammar A, Storr SJ, Green AR, Rakha E, Ellis IO et al (2018) IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients. Cancer immunol immunother CII 67(4):537\u2013549","journal-title":"Cancer immunol immunother CII"},{"key":"3616_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12935-017-0399-5","volume":"17","author":"CA Valle Oseguera","year":"2017","unstructured":"Valle Oseguera CA, Spencer JV (2017) Human cytomegalovirus interleukin-10 enhances matrigel invasion of MDA-MB-231 breast cancer cells. Cancer Cell Int 17:24","journal-title":"Cancer Cell Int"},{"issue":"1","key":"3616_CR46","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s00595-009-4016-7","volume":"40","author":"Y Toiyama","year":"2010","unstructured":"Toiyama Y, Miki C, Inoue Y, Minobe S, Urano H, Kusunoki M (2010) Loss of tissue expression of interleukin-10 promotes the disease progression of colorectal carcinoma. Surg Today 40(1):46\u201353","journal-title":"Surg Today"},{"issue":"4","key":"3616_CR47","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1172\/JCI118861","volume":"98","author":"DJ Berg","year":"1996","unstructured":"Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G et al (1996) Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Investig 98(4):1010\u20131020","journal-title":"J Clin Investig"},{"issue":"5","key":"3616_CR48","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.immuni.2014.03.012","volume":"40","author":"EBB Zigmond","year":"2014","unstructured":"Zigmond EBB, Friedlander G, Walker CR, Yona S, Kim KW, Brenner O, Krauthgamer R, Varol C, M\u00fcller W, Jung S (2014) Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. Immunity 40(5):720\u2013733","journal-title":"Immunity"},{"issue":"9","key":"3616_CR49","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.4049\/jimmunol.150.9.3755","volume":"150","author":"SEDT Macatonia","year":"1993","unstructured":"Macatonia SEDT, Knight SC, O\u2019Garra A (1993) Differential effect of IL-10 on dendritic cell-induced T cell proliferation and IFN-gamma production. J Immunol 150(9):3755\u20133765","journal-title":"J Immunol"},{"issue":"5","key":"3616_CR50","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.ccell.2018.10.007","volume":"34","author":"AIJ Naing","year":"2018","unstructured":"Naing AIJ, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Rojo B, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Pekarek KL, Wu V, Adamow M, McCauley S, Mumm JB, Wong P, Van Vlasselaer P, Leveque J, Tannir NM, Oft M (2018) PEGylated IL-10 (pegilodecakin) induces systemic immune activation, CD8+ T cell invigoration and polyclonal T cell expansion in cancer patients. Cancer Cell Int 34(5):775\u2013791","journal-title":"Cancer Cell Int"},{"issue":"2","key":"3616_CR51","doi-asserted-by":"publisher","first-page":"315","DOI":"10.31557\/APJCP.2021.22.2.315","volume":"22","author":"MN Fahmi","year":"2021","unstructured":"Fahmi MN, Pradjatmo H, Astuti I, Nindrea RD (2021) Cytokines as prognostic biomarkers of epithelial ovarian cancer (EOC): a systematic review and meta-analysis. Asian Pac J Cancer Prev 22(2):315\u2013323","journal-title":"Asian Pac J Cancer Prev"},{"issue":"12","key":"3616_CR52","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.ejca.2011.03.026","volume":"47","author":"R Yigit","year":"2011","unstructured":"Yigit R, Figdor CG, Zusterzeel PL, Pots JM, Torensma R, Massuger LF (2011) Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer. Eur J Cancer 47(12):1883\u20131889","journal-title":"Eur J Cancer"},{"key":"3616_CR53","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1146\/annurev.pathol.4.110807.092246","volume":"4","author":"KRSI Cho","year":"2009","unstructured":"Cho KRSI (2009) Ovarian cancer. Annu Rev Pathol 4:287\u2013313","journal-title":"Annu Rev Pathol"},{"issue":"8","key":"3616_CR54","first-page":"2875","volume":"29","author":"RL Giuntoli","year":"2009","unstructured":"Giuntoli RL, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, Oelke M (2009) Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res 29(8):2875\u20132884","journal-title":"Anticancer Res"},{"issue":"4","key":"3616_CR55","doi-asserted-by":"publisher","first-page":"e1111505","DOI":"10.1080\/2162402X.2015.1111505","volume":"5","author":"A Coosemans","year":"2016","unstructured":"Coosemans A, Decoene J, Baert T, Laenen A, Kasran A, Verschuere T et al (2016) Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course. Oncoimmunology 5(4):e1111505","journal-title":"Oncoimmunology"},{"issue":"6","key":"3616_CR56","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1080\/1354750X.2020.1783574","volume":"25","author":"DC Micheli","year":"2020","unstructured":"Micheli DC, Jammal MP, Martins-Filho A, Cortes J, Souza CN, Nomelini RS et al (2020) Serum cytokines and CXCR2: potential tumour markers in ovarian neoplasms. Biomarkers 25(6):474\u2013482","journal-title":"Biomarkers"},{"issue":"2","key":"3616_CR57","first-page":"2365","volume":"17","author":"L Zhang","year":"2019","unstructured":"Zhang L, Liu W, Wang X, Wang X, Sun H (2019) Prognostic value of serum IL-8 and IL-10 in patients with ovarian cancer undergoing chemotherapy. Oncol Lett 17(2):2365\u20132369","journal-title":"Oncol Lett"},{"issue":"9","key":"3616_CR58","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2174\/1871520617666170103100350","volume":"17","author":"II Antoneeva","year":"2017","unstructured":"Antoneeva II, Abakumova TV, Dolgova DR, Gening TP, Pirmamedova SS, Myasnikova DF et al (2017) Cytokine status of serum in ovarian cancer patients with different tumor neoadjuvant chemotherapy response. Anticancer Agents Med Chem 17(9):1251\u20131255","journal-title":"Anticancer Agents Med Chem"},{"issue":"12","key":"3616_CR59","doi-asserted-by":"publisher","first-page":"101217","DOI":"10.1016\/j.tranon.2021.101217","volume":"14","author":"D Hopkins","year":"2021","unstructured":"Hopkins D, Sanchez H, Berwin B, Wilkinson-Ryan I (2021) Cisplatin increases immune activity of monocytes and cytotoxic T-cells in a murine model of epithelial ovarian cancer. Transl Oncol 14(12):101217","journal-title":"Transl Oncol"},{"issue":"1","key":"3616_CR60","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s40425-019-0708-8","volume":"7","author":"HS Park","year":"2019","unstructured":"Park HS, Kwon WS, Park S, Jo E, Lim SJ, Lee CK et al (2019) Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer. J Immunother Cancer 7(1):268","journal-title":"J Immunother Cancer"},{"issue":"5","key":"3616_CR61","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1159\/000514356","volume":"39","author":"S Atta","year":"2021","unstructured":"Atta S, Kamel M, Mansour W, Hussein T, Maher K, Elrefaiy MA (2021) Ascitic fluid cytokines in chronic liver disease: a possible prognostic tool. Dig Dis 39(5):534\u2013539","journal-title":"Dig Dis"},{"issue":"8","key":"3616_CR62","first-page":"804","volume":"108","author":"ADBS Santin","year":"2001","unstructured":"Santin ADBS, Ravaggi A, Roman J, Smith CV, Pecorelli S, Cannon MJ, Parham GP (2001) Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG 108(8):804\u2013808","journal-title":"BJOG"},{"issue":"6","key":"3616_CR63","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.3892\/or.2016.5136","volume":"36","author":"Q Zhu","year":"2016","unstructured":"Zhu Q, Wu X, Wu Y, Wang X (2016) Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer. Oncol Rep 36(6):3472\u20133478","journal-title":"Oncol Rep"},{"issue":"5","key":"3616_CR64","doi-asserted-by":"publisher","first-page":"297","DOI":"10.51620\/0869-2084-2021-66-5-297-303","volume":"66","author":"SOAT Gening","year":"2021","unstructured":"Gening SOAT, Antoneeva II, Rizvanov AA, Gening TP, Gafurbaeva DU (2021) Stem-like tumor cells and proinflammatory cytokines in the ascitic fluid of ovarian cancer patients. Klin Lab Diagn 66(5):297\u2013303","journal-title":"Klin Lab Diagn"},{"issue":"4","key":"3616_CR65","first-page":"705","volume":"106","author":"A Naldini","year":"2011","unstructured":"Naldini A, Morena E, Belotti D, Carraro F, Allavena P, Giavazzi R (2011) Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks. Thromb Haemost 106(4):705\u2013711","journal-title":"Thromb Haemost"},{"issue":"7","key":"3616_CR66","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1177\/1933719112466299","volume":"20","author":"EB Candido","year":"2013","unstructured":"Candido EB, Silva LM, Carvalho AT, Lamaita RM, Filho RM, Cota BD et al (2013) Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer. Reprod Sci 20(7):828\u2013837","journal-title":"Reprod Sci"},{"issue":"5","key":"3616_CR67","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/cncr.11618","volume":"98","author":"T Sasada","year":"2003","unstructured":"Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A (2003) CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98(5):1089\u20131099","journal-title":"Cancer"},{"issue":"44","key":"3616_CR68","doi-asserted-by":"publisher","first-page":"76843","DOI":"10.18632\/oncotarget.20164","volume":"8","author":"LDZ Wu","year":"2017","unstructured":"Wu LDZ, Peng Y, Han L, Liu J, Wang L, Li B, Zhao J, Jiao S, Wei H (2017) Ascites-derived IL-6 and IL-10 synergistically expand CD14+HLA-DR-\/low myeloid-derived suppressor cells in ovarian cancer patients. Oncotarget 8(44):76843\u201376856","journal-title":"Oncotarget"},{"key":"3616_CR69","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/ni1102-999","volume":"3","author":"HTRN Khong","year":"2002","unstructured":"Khong HTRN (2002) Natural selection of tumor variants in the generation of \u201ctumor escape\u201d phenotypes. Nat Immunol 3:999\u20131005","journal-title":"Nat Immunol"},{"issue":"8","key":"3616_CR70","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.biocel.2004.01.020","volume":"36","author":"H Kawamoto","year":"2004","unstructured":"Kawamoto H, Minato N (2004) Myeloid cells. Int J Biochem Cell Biol 36(8):1374\u20131379","journal-title":"Int J Biochem Cell Biol"},{"issue":"15","key":"3616_CR71","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.3390\/cancers13153772","volume":"13","author":"AFJ Dou","year":"2021","unstructured":"Dou AFJ (2021) Heterogeneous myeloid cells in tumors. Cancers (Basel) 13(15):3772","journal-title":"Cancers (Basel)"},{"key":"3616_CR72","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3389\/fimmu.2011.00029","volume":"2","author":"KM Hart","year":"2011","unstructured":"Hart KM, Byrne KT, Molloy MJ, Usherwood EM, Berwin B (2011) IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer. Front Immunol 2:29","journal-title":"Front Immunol"},{"issue":"6","key":"3616_CR73","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/icb.2014.13","volume":"92","author":"KM Hart","year":"2014","unstructured":"Hart KM, Usherwood EJ, Berwin BL (2014) CX3CR1 delineates temporally and functionally distinct subsets of myeloid-derived suppressor cells in a mouse model of ovarian cancer. Immunol Cell Biol 92(6):499\u2013508","journal-title":"Immunol Cell Biol"},{"issue":"8","key":"3616_CR74","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s13238-017-0466-7","volume":"9","author":"B Zhang","year":"2018","unstructured":"Zhang B, Chen F, Xu Q, Han L, Xu J, Gao L et al (2018) Revisiting ovarian cancer microenvironment: a friend or a foe? Protein Cell 9(8):674\u2013692","journal-title":"Protein Cell"},{"issue":"2","key":"3616_CR75","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s11670-012-0130-y","volume":"24","author":"CZ Liu","year":"2012","unstructured":"Liu CZ, Zhang L, Chang XH, Cheng YX, Cheng HY, Ye X et al (2012) Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer. Chin J Cancer Res 24(2):130\u2013137","journal-title":"Chin J Cancer Res"},{"issue":"7","key":"3616_CR76","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/nm1201-1339","volume":"12","author":"WMV Zou","year":"2001","unstructured":"Zou WMV, Coulomb-L\u2019Hermin A, Borvak J, Nome F, Isaeva T, Wei S, Krzysiek R, Durand-Gasselin I, Gordon A, Pustilnik T, Curiel DT, Galanaud P, Capron F, Emilie D, Curiel TJ (2001) Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 12(7):1339\u20131346","journal-title":"Nat Med"},{"issue":"12","key":"3616_CR77","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1158\/0008-5472.CAN-04-4043","volume":"65","author":"SKI Wei","year":"2005","unstructured":"Wei SKI, Zou L, Daniel B, Cheng P, Mottram P, Curiel T, Lange A, Zou W (2005) Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res 65(12):5020\u20135026","journal-title":"Cancer Res"},{"issue":"16","key":"3616_CR78","doi-asserted-by":"publisher","first-page":"5423","DOI":"10.1158\/0008-5472.CAN-11-0367","volume":"71","author":"SI Labidi-Galy","year":"2011","unstructured":"Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A et al (2011) Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 71(16):5423\u20135434","journal-title":"Cancer Res"},{"key":"3616_CR79","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fonc.2014.00137","volume":"4","author":"EK Colvin","year":"2014","unstructured":"Colvin EK (2014) Tumor-associated macrophages contribute to tumor progression in ovarian cancer. Front Oncol 4:137","journal-title":"Front Oncol"},{"issue":"9","key":"3616_CR80","doi-asserted-by":"publisher","first-page":"e51981","DOI":"10.15252\/embr.202051981","volume":"22","author":"A Menga","year":"2021","unstructured":"Menga A, Favia M, Spera I, Vegliante MC, Gissi R, De Grassi A et al (2021) N-acetylaspartate release by glutaminolytic ovarian cancer cells sustains protumoral macrophages. EMBO Rep 22(9):e51981","journal-title":"EMBO Rep"},{"issue":"11","key":"3616_CR81","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.4049\/jimmunol.163.11.6251","volume":"163","author":"AENM Loercher","year":"1999","unstructured":"Loercher AENM, Kavanagh JJ, Platsoucas CD, Freedman RS (1999) Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol 163(11):6251\u20136260","journal-title":"J Immunol"},{"issue":"6","key":"3616_CR82","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41590-019-0346-9","volume":"20","author":"DV Sawant","year":"2019","unstructured":"Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C et al (2019) Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion. Nat Immunol 20(6):724\u2013735","journal-title":"Nat Immunol"},{"key":"3616_CR83","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1146\/annurev-immunol-020711-074934","volume":"30","author":"C Mauri","year":"2012","unstructured":"Mauri C, Bosma A (2012) Immune regulatory function of B cells. Annu Rev Immunol 30:221\u2013241","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"3616_CR84","doi-asserted-by":"publisher","first-page":"6581","DOI":"10.1007\/s13277-015-4538-0","volume":"37","author":"XJY Wei","year":"2016","unstructured":"Wei XJY, Tian Y, Zhang H, Wu J, Lu W, Lu X (2016) Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients. Tumour Biol 37(5):6581\u20136588","journal-title":"Tumour Biol"},{"issue":"1","key":"3616_CR85","doi-asserted-by":"publisher","first-page":"13083","DOI":"10.1038\/s41598-019-49581-4","volume":"9","author":"Y Murakami","year":"2019","unstructured":"Murakami Y, Saito H, Shimizu S, Kono Y, Shishido Y, Miyatani K et al (2019) Increased regulatory B cells are involved in immune evasion in patients with gastric cancer. Sci Rep 9(1):13083","journal-title":"Sci Rep"},{"issue":"2","key":"3616_CR86","doi-asserted-by":"publisher","first-page":"263","DOI":"10.5114\/ceji.2015.52840","volume":"40","author":"LBG Qian","year":"2015","unstructured":"Qian LBG, Zhou Y, Wang Y, Hu J, Liu X, Xu Y (2015) Clinical significance of regulatory B cells in the peripheral blood of patients with oesophageal cancer. Cent Eur J Immunol 40(2):263\u2013265","journal-title":"Cent Eur J Immunol"},{"key":"3616_CR87","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.oraloncology.2015.11.003","volume":"53","author":"XSY Zhou","year":"2016","unstructured":"Zhou XSY, Lao XM, Liang YJ, Liao GQ (2016) CD19(+)IL-10(+) regulatory B cells affect survival of tongue squamous cell carcinoma patients and induce resting CD4(+) T cells to CD4(+)Foxp3(+) regulatory T cells. Oral Oncol 53:27\u201335","journal-title":"Oral Oncol"},{"issue":"7","key":"3616_CR88","doi-asserted-by":"publisher","first-page":"e1180485","DOI":"10.1080\/2162402X.2016.1180485","volume":"5","author":"M Zhou","year":"2016","unstructured":"Zhou M, Wen Z, Cheng F, Ma J, Li W, Ren H et al (2016) Tumor-released autophagosomes induce IL-10-producing B cells with suppressive activity on T lymphocytes via TLR2-MyD88-NF-kappaB signal pathway. Oncoimmunology 5(7):e1180485","journal-title":"Oncoimmunology"},{"issue":"6","key":"3616_CR89","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s002620100196","volume":"50","author":"SSA Berger","year":"2001","unstructured":"Berger SSA, Denkert C, K\u00f6bel M, Hauptmann S (2001) Interleukin-10 in serous ovarian carcinoma cell lines. Cancer Immunol Immunother 50(6):328\u2013333","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"3616_CR90","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00262-007-0347-7","volume":"57","author":"TM Carr","year":"2008","unstructured":"Carr TM, Adair SJ, Fink MJ, Hogan KT (2008) Immunological profiling of a panel of human ovarian cancer cell lines. Cancer Immunol Immunother 57(1):31\u201342","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"3616_CR91","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1365-3083.2009.02350.x","volume":"71","author":"M Nowak","year":"2010","unstructured":"Nowak M, Klink M, Glowacka E, Sulowska Z, Kulig A, Szpakowski M et al (2010) Production of cytokines during interaction of peripheral blood mononuclear cells with autologous ovarian cancer cells or benign ovarian tumour cells. Scand J Immunol 71(2):91\u201398","journal-title":"Scand J Immunol"},{"issue":"1","key":"3616_CR92","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s40425-019-0666-1","volume":"7","author":"S Raghavan","year":"2019","unstructured":"Raghavan S, Mehta P, Xie Y, Lei YL, Mehta G (2019) Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments. J Immunother Cancer 7(1):190","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3616_CR93","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/ijc.2910550118","volume":"55","author":"GAAJ Gastl","year":"1993","unstructured":"Gastl GAAJ, Nanus DM, Oosterkamp R, Silver J, Liu F, Chen M, Albino AP, Bander NH (1993) Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 55(1):96\u2013101","journal-title":"Int J Cancer"},{"issue":"2A","key":"3616_CR94","first-page":"1077","volume":"19","author":"JYY Hihara","year":"1999","unstructured":"Hihara JYY, Minami K, Noma K, Toge T (1999) Down-regulation of IL-10 enhances the efficacy of locoregional immunotherapy using OK-432 against malignant effusion. Anticancer Res 19(2A):1077\u20131084","journal-title":"Anticancer Res"},{"issue":"11\u201312","key":"3616_CR95","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1023\/A:1022260711583","volume":"18","author":"PGA Mukherjee","year":"2001","unstructured":"Mukherjee PGA, Madsen CS, Tinder TL, Jacobs F, Parker J, Agrawal B, Longenecker BM, Gendler SJ (2001) MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment. Glycoconj J 18(11\u201312):931\u2013942","journal-title":"Glycoconj J"},{"issue":"2","key":"3616_CR96","doi-asserted-by":"publisher","first-page":"e12736","DOI":"10.1111\/sji.12736","volume":"89","author":"X Ke","year":"2019","unstructured":"Ke X, Shen L (2019) Targeting cytokines secreted by CD4(+) CD25(high) CD127(low) regulatory T cells inhibits ovarian cancer progression. Scand J Immunol 89(2):e12736","journal-title":"Scand J Immunol"},{"issue":"1","key":"3616_CR97","doi-asserted-by":"publisher","first-page":"145","DOI":"10.4049\/jimmunol.1203165","volume":"191","author":"B Santner-Nanan","year":"2013","unstructured":"Santner-Nanan B, Straubinger K, Hsu P, Parnell G, Tang B, Xu B et al (2013) Fetal-maternal alignment of regulatory T cells correlates with IL-10 and Bcl-2 upregulation in pregnancy. J Immunol 191(1):145\u2013153","journal-title":"J Immunol"},{"issue":"19","key":"3616_CR98","doi-asserted-by":"publisher","first-page":"9066","DOI":"10.1158\/0008-5472.CAN-07-0575","volume":"67","author":"HW Lo","year":"2007","unstructured":"Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y et al (2007) Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 67(19):9066\u20139076","journal-title":"Cancer Res"},{"issue":"6","key":"3616_CR99","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1089\/107999099313695","volume":"19","author":"RP Donnelly","year":"1999","unstructured":"Donnelly RP, Dickensheets H, Finbloom DS (1999) The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interf Cytokine Res 19(6):563\u2013573","journal-title":"J Interf Cytokine Res"},{"issue":"3","key":"3616_CR100","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.4049\/jimmunol.155.3.1079","volume":"155","author":"DS Finbloom","year":"1995","unstructured":"Finbloom DS, Winestock KD (1995) IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J Immunol 155(3):1079\u20131090","journal-title":"J Immunol"},{"issue":"3","key":"3616_CR101","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/0014-5793(96)00990-8","volume":"394","author":"J Wehinger","year":"1996","unstructured":"Wehinger J, Gouilleux F, Groner B, Finke J, Mertelsmann R, Weber-Nordt RM (1996) IL-10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, and Stat5) and their distinct combinatorial assembly in the promoters of selected genes. FEBS Lett 394(3):365\u2013370","journal-title":"FEBS Lett"},{"issue":"4","key":"3616_CR102","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/ijc.32151","volume":"145","author":"L Yang","year":"2019","unstructured":"Yang L, Dong Y, Li Y, Wang D, Liu S, Wang D et al (2019) IL-10 derived from M2 macrophage promotes cancer stemness via JAK1\/STAT1\/NF-kappaB\/Notch1 pathway in non-small cell lung cancer. Int J Cancer 145(4):1099\u20131110","journal-title":"Int J Cancer"},{"issue":"4","key":"3616_CR103","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semcdb.2008.06.004","volume":"19","author":"G Regis","year":"2008","unstructured":"Regis G, Pensa S, Boselli D, Novelli F, Poli V (2008) Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling. Semin Cell Dev Biol 19(4):351\u2013359","journal-title":"Semin Cell Dev Biol"},{"issue":"8","key":"3616_CR104","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.4049\/jimmunol.167.8.4436","volume":"167","author":"JH Zhou","year":"2001","unstructured":"Zhou JH, Broussard SR, Strle K, Freund GG, Johnson RW, Dantzer R et al (2001) IL-10 inhibits apoptosis of promyeloid cells by activating insulin receptor substrate-2 and phosphatidylinositol 3\u2032-kinase. J Immunol 167(8):4436\u20134442","journal-title":"J Immunol"},{"issue":"6","key":"3616_CR105","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1172\/JCI117618","volume":"94","author":"S Reitamo","year":"1994","unstructured":"Reitamo S, Remitz A, Tamai K, Uitto J (1994) Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts. J Clin Invest 94(6):2489\u20132492","journal-title":"J Clin Invest"},{"key":"3616_CR106","doi-asserted-by":"publisher","first-page":"1161067","DOI":"10.3389\/fimmu.2023.1161067","volume":"14","author":"V Carlini","year":"2023","unstructured":"Carlini V, Noonan DM, Abdalalem E, Goletti D, Sansone C, Calabrone L et al (2023) The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. Front Immunol 14:1161067","journal-title":"Front Immunol"},{"issue":"9","key":"3616_CR107","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.trecan.2023.05.003","volume":"9","author":"MA Salkeni","year":"2023","unstructured":"Salkeni MA, Naing A (2023) Interleukin-10 in cancer immunotherapy: from bench to bedside. Trends Cancer 9(9):716\u2013725","journal-title":"Trends Cancer"},{"issue":"29","key":"3616_CR108","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.2217\/fon-2022-0063","volume":"18","author":"KSCA Rallis","year":"2022","unstructured":"Rallis KSCA, Dadah H, Stanislovas J, Zamani P, Makker S, Szabados B, Sideris M (2022) IL-10 in cancer: an essential thermostatic regulator between homeostatic immunity and inflammation\u2014a comprehensive review. Future Oncol 18(29):3349\u20133365","journal-title":"Future Oncol"},{"issue":"6","key":"3616_CR109","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41590-021-00940-2","volume":"22","author":"Y Guo","year":"2021","unstructured":"Guo Y, Xie YQ, Gao M, Zhao Y, Franco F, Wenes M et al (2021) Metabolic reprogramming of terminally exhausted CD8(+) T cells by IL-10 enhances anti-tumor immunity. Nat Immunol 22(6):746\u2013756","journal-title":"Nat Immunol"},{"issue":"29","key":"3616_CR110","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1200\/JCO.2016.68.1106","volume":"34","author":"A Naing","year":"2016","unstructured":"Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ et al (2016) Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. J Clin Oncol Off J Am Soc Clin Oncol 34(29):3562\u20133569","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"3616_CR111","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1200\/JCO.20.02232","volume":"39","author":"JRLS Hecht","year":"2021","unstructured":"Hecht JRLS, Bendell J, Sim HW, Macarulla T, Lopez CD, Van Cutsem E, Mu\u00f1oz Martin AJ, Park JO, Greil R, Wang H, Hozak RR, Gueorguieva I, Lin Y, Rao S, Ryoo BY (2021) Randomized phase III study of FOLFOX alone or with pegilodecakin as second-line therapy in patients with metastatic pancreatic cancer that progressed after gemcitabine (SEQUOIA). J Clin Oncol 39(10):1108\u20131118","journal-title":"J Clin Oncol"},{"issue":"2","key":"3616_CR112","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11912-019-0760-z","volume":"21","author":"K Autio","year":"2019","unstructured":"Autio K, Oft M (2019) Pegylated interleukin-10: clinical development of an immunoregulatory cytokine for use in cancer therapeutics. Curr Oncol Rep 21(2):19","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"3616_CR113","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1124\/pr.55.2.4","volume":"55","author":"K Asadullah","year":"2003","unstructured":"Asadullah K, Sterry W, Volk HD (2003) Interleukin-10 therapy\u2013review of a new approach. Pharmacol Rev 55(2):241\u2013269","journal-title":"Pharmacol Rev"},{"issue":"23","key":"3616_CR114","doi-asserted-by":"publisher","first-page":"6667","DOI":"10.1158\/0008-5472.CAN-17-0740","volume":"77","author":"P Lamichhane","year":"2017","unstructured":"Lamichhane P, Karyampudi L, Shreeder B, Krempski J, Bahr D, Daum J et al (2017) IL10 release upon PD-1 blockade sustains immunosuppression in ovarian cancer. Cancer Res 77(23):6667\u20136678","journal-title":"Cancer Res"},{"issue":"2","key":"3616_CR115","doi-asserted-by":"publisher","first-page":"e000875","DOI":"10.1136\/jitc-2020-000875","volume":"8","author":"SFGA Adams","year":"2020","unstructured":"Adams SFGA, Chiang CL, Mookerjee A, Flies D, Jean S, McCann GA, Michaux J, Pak H, Huber F, Neal C, Dangaj D, Bassani-Sternberg M, Rusakiewicz S, Facciabene A, Coukos G, Gimotty PA, Kandalaft LE (2020) Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes. J Immunother Cancer 8(2):e000875","journal-title":"J Immunother Cancer"},{"issue":"4","key":"3616_CR116","first-page":"5384","volume":"15","author":"Z Hu","year":"2018","unstructured":"Hu Z, Hu S, Wu Y, Li S, He C, Xing X et al (2018) Accumulation and suppressive function of regulatory T cells in malignant ascites: reducing their suppressive function using arsenic trioxide in vitro. Oncol Lett 15(4):5384\u20135390","journal-title":"Oncol Lett"},{"key":"3616_CR117","doi-asserted-by":"publisher","first-page":"724104","DOI":"10.3389\/fonc.2021.724104","volume":"11","author":"A Martincuks","year":"2021","unstructured":"Martincuks A, Song J, Kohut A, Zhang C, Li YJ, Zhao Q et al (2021) PARP inhibition activates STAT3 in both tumor and immune cells underlying therapy resistance and immunosuppression in ovarian cancer. Front Oncol 11:724104","journal-title":"Front Oncol"},{"issue":"4","key":"3616_CR118","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/j.jamcollsurg.2017.07.645","volume":"225","author":"OV Gruzdyn","year":"2017","unstructured":"Gruzdyn OV, Gruber SA, Batchu RB, Mahmud EM, Chukr FK, Dachepalli R (2017) Mesothelin chimeric antigen receptor (car)-mediated therapy for ovarian cancer. J Am Coll Surg 225(4):e47","journal-title":"J Am Coll Surg"},{"key":"3616_CR119","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-3-030-55617-4_3","volume":"1290","author":"RBGO Batchu","year":"2021","unstructured":"Batchu RBGO, Kolli BK, Dachepalli R, Umar PS, Rai SK, Singh N, Tavva PS, Weaver DW, Gruber SA (2021) IL-10 signaling in the tumor microenvironment of ovarian cancer. Adv Exp Med Biol 1290:51\u201365","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"3616_CR120","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1021\/mp060132k","volume":"4","author":"YHTC Chen","year":"2007","unstructured":"Chen YHTC, Huang PY, Chang MY, Cheng PC, Chou CH, Chen DH, Wang CR, Shiau AL, Wu CL (2007) Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model. Mol Pharm 4(5):713\u2013722","journal-title":"Mol Pharm"},{"key":"3616_CR121","first-page":"753","volume":"5","author":"MI Sriram","year":"2010","unstructured":"Sriram MI, Kanth SB, Kalishwaralal K, Gurunathan S (2010) Antitumor activity of silver nanoparticles in Dalton\u2019s lymphoma ascites tumor model. Int J Nanomed 5:753\u2013762","journal-title":"Int J Nanomed"},{"issue":"5","key":"3616_CR122","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1111\/cas.15321","volume":"113","author":"S Hama","year":"2022","unstructured":"Hama S, Nishi T, Isono E, Itakura S, Yoshikawa Y, Nishimoto A et al (2022) Intraperitoneal administration of nanoparticles containing tocopheryl succinate prevents peritoneal dissemination. Cancer Sci 113(5):1779\u20131788","journal-title":"Cancer Sci"},{"issue":"7","key":"3616_CR123","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.7150\/thno.42385","volume":"10","author":"X Dai","year":"2020","unstructured":"Dai X, Meng J, Deng S, Zhang L, Wan C, Lu L et al (2020) Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel. Theranostics 10(7):3049\u20133063","journal-title":"Theranostics"},{"key":"3616_CR124","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.biomaterials.2019.02.017","volume":"203","author":"EA Shamskhou","year":"2019","unstructured":"Shamskhou EA, Kratochvil MJ, Orcholski ME, Nagy N, Kaber G, Steen E et al (2019) Hydrogel-based delivery of Il-10 improves treatment of bleomycin-induced lung fibrosis in mice. Biomaterials 203:52\u201362","journal-title":"Biomaterials"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03616-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03616-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03616-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:02:22Z","timestamp":1708473742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03616-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,27]]},"references-count":124,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["3616"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03616-y","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,27]]},"assertion":[{"value":"20 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"N\/A","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"32"}}